Premier Path Wealth Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Premier Path Wealth Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$312K	Sell	412 -95	-19%	-$71.8K	0.04%	317
2026 Q2	$316K	Sell	507 -160	-24%	-$109K	0.04%	355
2026 Q1	$515K	Buy	667 +130	+24%	+$100K	0.07%	266
2025 Q4	$414K	Buy	+537	New	+$365K	0.05%	275
2025 Q2	–	Sell	-344	Closed	-$218K	–	396
2025 Q1	$218K	Buy	+344	New	+$237K	0.03%	354
2024 Q4	–	Sell	-625	Closed	-$657K	–	384
2024 Q3	$657K	Buy	625 +5	+0.8%	+$5.56K	0.1%	201
2024 Q2	$651K	Buy	620 +62	+11%	+$60.1K	0.11%	188
2024 Q1	$537K	Buy	558 +42	+8%	+$39.9K	0.1%	200
2023 Q4	$453K	Buy	+516	New	+$425K	0.1%	202

Other funds holding REGN

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $127B AUM 33.25% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

Premier Path Wealth Partners's REGN Position: Q3 2026 in Review

Premier Path Wealth Partners reduced its Regeneron Pharmaceuticals (REGN) stake by 19% in Q3 2026, selling an estimated $71.8K and leaving 412 shares worth $312K. The position accounts for 0.04% of the portfolio, ranked #317.

Premier Path Wealth Partners first reported a position in REGN in Q4 2023 and has held it in 9 quarters since. The position peaked at $657K in Q3 2024. 817 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

Premier Path Wealth Partners held 412 shares of Regeneron Pharmaceuticals worth $312K as of Q3 2026.
Premier Path Wealth Partners sold 95 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $71.8K.
Regeneron Pharmaceuticals made up 0.04% of Premier Path Wealth Partners's portfolio in Q3 2026, its #317 holding.
Premier Path Wealth Partners first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 9 quarters since.
Premier Path Wealth Partners's Regeneron Pharmaceuticals position peaked at $657K in Q3 2024.
817 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Premier Path Wealth Partners's 13F filing for Q3 2026, filed 16 Oct 2026.